| abstract |
The invention relates to the use of NEP-associated molecules, such as inhibitors, activators or substrates for producing a medicament for the diagnosis, prophylaxis, treatment, after-care and/or for monitoring the course of non-immunogenic, non-hypertensive civilisation diseases, in particular obesity and Alzheimer's disease. The invention also relates to the use of genetically modified animals for analysing obesity and Alzheimer's disease, in addition to a method for treating eating disorders and dementia and to a method for identifying molecules associated with eating disorders and/or Alzheimer's disease. |